FibroGen Inc (FGEN)
0.3954
+0.01
(+2.12%)
USD |
NASDAQ |
Nov 22, 16:00
0.40
0.00 (0.00%)
After-Hours: 20:00
FibroGen Cash from Financing (Quarterly): -0.127M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.127M |
| June 30, 2024 | 0.032M |
| March 31, 2024 | -0.165M |
| December 31, 2023 | -0.246M |
| September 30, 2023 | -0.022M |
| June 30, 2023 | 91.53M |
| March 31, 2023 | 31.48M |
| December 31, 2022 | 48.67M |
| September 30, 2022 | -1.092M |
| June 30, 2022 | 2.087M |
| March 31, 2022 | -2.893M |
| December 31, 2021 | -0.031M |
| September 30, 2021 | -0.833M |
| June 30, 2021 | 2.381M |
| March 31, 2021 | -2.08M |
| December 31, 2020 | 5.659M |
| September 30, 2020 | 4.225M |
| June 30, 2020 | 4.649M |
| March 31, 2020 | -1.19M |
| December 31, 2019 | -0.284M |
| September 30, 2019 | -3.236M |
| June 30, 2019 | 2.754M |
| Date | Value |
|---|---|
| March 31, 2019 | -3.534M |
| December 31, 2018 | 2.818M |
| September 30, 2018 | 3.92M |
| June 30, 2018 | 5.092M |
| March 31, 2018 | 2.045M |
| December 31, 2017 | 3.413M |
| September 30, 2017 | 370.02M |
| June 30, 2017 | 122.46M |
| March 31, 2017 | 0.574M |
| December 31, 2016 | 3.145M |
| September 30, 2016 | 1.089M |
| June 30, 2016 | 2.653M |
| March 31, 2016 | -0.149M |
| December 31, 2015 | 4.125M |
| September 30, 2015 | 2.814M |
| June 30, 2015 | 4.787M |
| March 31, 2015 | 0.62M |
| December 31, 2014 | 175.66M |
| September 30, 2014 | -1.034M |
| June 30, 2014 | -0.473M |
| March 31, 2014 | -0.064M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.893M
Minimum
Mar 2022
91.53M
Maximum
Jun 2023
9.088M
Average
-0.0265M
Median
Cash from Financing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -499.12M |
| Arbutus Biopharma Corp | 1.775M |
| GlycoMimetics Inc | 0.00 |
| Cidara Therapeutics Inc | -0.182M |
| Cue Biopharma Inc | 9.821M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.376M |
| Cash from Investing (Quarterly) | 0.755M |
| Free Cash Flow | -126.23M |
| Free Cash Flow Per Share (Quarterly) | -0.0841 |
| Free Cash Flow to Equity (Quarterly) | -8.759M |
| Free Cash Flow to Firm (Quarterly) | -7.265M |
| Free Cash Flow Yield | -321.0% |